Penumbra Inc
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also… Read more
Penumbra Inc (PEN) - Net Assets
Latest net assets as of September 2025: $1.36 Billion USD
Based on the latest financial reports, Penumbra Inc (PEN) has net assets worth $1.36 Billion USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.74 Billion) and total liabilities ($385.67 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.36 Billion |
| % of Total Assets | 77.89% |
| Annual Growth Rate | N/A |
| 5-Year Change | 80.46% |
| 10-Year Change | 394.98% |
| Growth Volatility | 17.99 |
Penumbra Inc - Net Assets Trend (2013–2024)
This chart illustrates how Penumbra Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Penumbra Inc (2013–2024)
The table below shows the annual net assets of Penumbra Inc from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $1.15 Billion | -2.38% |
| 2023-12-31 | $1.18 Billion | +18.03% |
| 2022-12-31 | $998.86 Million | +4.71% |
| 2021-12-31 | $953.93 Million | +49.57% |
| 2020-12-31 | $637.79 Million | +31.34% |
| 2019-12-31 | $485.61 Million | +14.96% |
| 2018-12-31 | $422.42 Million | +5.50% |
| 2017-12-31 | $400.41 Million | +50.22% |
| 2016-12-31 | $266.55 Million | +14.63% |
| 2015-12-31 | $232.52 Million | +1979.73% |
| 2014-12-31 | $-12.37 Million | -53.44% |
| 2013-12-31 | $-8.06 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Penumbra Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 7499700000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $60.00 Million | 5.21% |
| Common Stock | $38.00K | 0.00% |
| Other Comprehensive Income | $-5.84 Million | -0.51% |
| Other Components | $1.10 Billion | 95.29% |
| Total Equity | $1.15 Billion | 100.00% |
Penumbra Inc Competitors by Market Cap
The table below lists competitors of Penumbra Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ArcelorMittal SA
PINK:AMSYF
|
$12.85 Billion |
|
Guidewire Software Inc
NYSE:GWRE
|
$12.85 Billion |
|
Vedanta Limited
NSE:VEDL
|
$12.88 Billion |
|
Gaming & Leisure Properties
NASDAQ:GLPI
|
$12.88 Billion |
|
Banco Do Brasil SA
PINK:BDORY
|
$12.80 Billion |
|
Jiangxi Copper Co Ltd Class A
SHG:600362
|
$12.79 Billion |
|
RPM International Inc
NYSE:RPM
|
$12.78 Billion |
|
Masco Corporation
NYSE:MAS
|
$12.77 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Penumbra Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,178,944,000 to 1,150,931,000, a change of -28,013,000 (-2.4%).
- Net income of 14,012,000 contributed positively to equity growth.
- Share repurchases of 100,387,000 reduced equity.
- Other comprehensive income decreased equity by 2,692,000.
- Other factors increased equity by 61,054,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $14.01 Million | +1.22% |
| Share Repurchases | $100.39 Million | -8.72% |
| Other Comprehensive Income | $-2.69 Million | -0.23% |
| Other Changes | $61.05 Million | +5.3% |
| Total Change | $- | -2.38% |
Book Value vs Market Value Analysis
This analysis compares Penumbra Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 11.53x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $-0.33 | $338.00 | x |
| 2014-12-31 | $-0.50 | $338.00 | x |
| 2015-12-31 | $16.35 | $338.00 | x |
| 2016-12-31 | $7.96 | $338.00 | x |
| 2017-12-31 | $11.34 | $338.00 | x |
| 2018-12-31 | $11.70 | $338.00 | x |
| 2019-12-31 | $13.40 | $338.00 | x |
| 2020-12-31 | $17.94 | $338.00 | x |
| 2021-12-31 | $25.18 | $338.00 | x |
| 2022-12-31 | $26.40 | $338.00 | x |
| 2023-12-31 | $30.06 | $338.00 | x |
| 2024-12-31 | $29.31 | $338.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Penumbra Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.22%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.17%
- • Asset Turnover: 0.78x
- • Equity Multiplier: 1.33x
- Recent ROE (1.22%) is below the historical average (2.11%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.00% | 4.61% | 1.25x | 0.00x | $4.91 Million |
| 2014 | 0.00% | 1.79% | 1.03x | 0.00x | $3.48 Million |
| 2015 | 1.02% | 1.27% | 0.71x | 1.13x | $-20.89 Million |
| 2016 | 5.56% | 5.63% | 0.85x | 1.16x | $-11.84 Million |
| 2017 | 1.16% | 1.40% | 0.70x | 1.19x | $-35.38 Million |
| 2018 | 1.56% | 1.48% | 0.86x | 1.22x | $-35.62 Million |
| 2019 | 9.97% | 8.85% | 0.82x | 1.37x | $-131.20K |
| 2020 | -3.00% | -3.44% | 0.68x | 1.28x | $-83.41 Million |
| 2021 | 0.27% | 0.35% | 0.60x | 1.30x | $-92.77 Million |
| 2022 | -0.20% | -0.24% | 0.62x | 1.37x | $-101.89 Million |
| 2023 | 7.71% | 8.59% | 0.68x | 1.32x | $-26.94 Million |
| 2024 | 1.22% | 1.17% | 0.78x | 1.33x | $-101.08 Million |
Industry Comparison
This section compares Penumbra Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Penumbra Inc (PEN) | $1.36 Billion | 0.00% | 0.28x | $12.84 Billion |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |